CREATES Act of 2017
Latest action · Apr 28, 2017 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedApr 27, 2017
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Creating and Restoring Equal Access To Equivalent Samples Act of 2017 or the CREATES Act of 2017
This bill permits the developer of a drug or biological product to bring a civil action against the license holder of an approved drug or biological product if the holder has declined to make available sufficient quantities of the approved drug or product for the developer's testing.
Cosponsors 25
Members who signed on, in the order they did. Signatures ran from Apr 27, 2017 to Sep 28, 2018; 1 is an original cosponsor, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-RI | David N. Cicilline | Original | Apr 27, 2017 |
| R-NC | Mark Meadows | Feb 6, 2018 | |
| D-VT | Peter Welch | Feb 6, 2018 | |
| D-TN | Steve Cohen | Feb 8, 2018 | |
| R-IN | Todd Rokita | Feb 8, 2018 | |
| R-FL | Francis Rooney | Feb 20, 2018 | |
| D-OH | Marcy Kaptur | Feb 20, 2018 | |
| D-NH | Carol Shea-Porter | Feb 23, 2018 | |
| R-WI | Mike Gallagher | Feb 23, 2018 | |
| D-DC | Eleanor Holmes Norton | Mar 8, 2018 | |
| R-TN | John J. Duncan, Jr. | Mar 8, 2018 | |
| R-TX | John Abney Culberson | Mar 13, 2018 | |
| D-TX | Lloyd Doggett | Mar 13, 2018 | |
| D-MS | Bennie G. Thompson | Mar 15, 2018 | |
| R-VA | Dave Brat | Mar 15, 2018 | |
| R-OH | Bob Gibbs | Apr 17, 2018 | |
| D-IL | Janice D. Schakowsky | Apr 17, 2018 | |
| R-KY | Andy Barr | May 3, 2018 | |
| D-OR | Peter A. DeFazio | May 3, 2018 | |
| D-TX | Beto O'Rourke | Jun 6, 2018 | |
| R-OH | James B. Renacci | Jun 6, 2018 | |
| D-MD | Jamie Raskin | Aug 10, 2018 | |
| R-NY | Peter T. King | Aug 10, 2018 | |
| D-IL | Daniel Lipinski | Sep 28, 2018 | |
| R-WI | Glenn Grothman | Sep 28, 2018 |
Committees 2
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Apr 27, 2017 |
| Health Subcommittee | Referred Apr 28, 2017 | |
| House | Judiciary Committee | Referred Apr 27, 2017 |
Actions 3
Everything that happened, newest first.
- Apr 28, 2017Referred to the Subcommittee on Health.
- Apr 27, 2017Introduced in House
- Apr 27, 2017Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 163, no. 72, April 27, 2017, page H2942.
Printed hearings 2
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| Serial No. 115-28 | THE PHARMACEUTICAL SUPPLY CHAIN: THE PROPOSED MERGER OF CVS HEALTH AND AETNA43 pages | Judiciary Committee | Feb 27, 2018 |
| S. Hrg. 115-869 | THE COST OF PRESCRIPTION DRUGS: AN EXAMINATION OF THE NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE REPORT "MAKING MEDICINES AFFORDABLE: A NATIONAL IMPERATIVE"60 pages | Health, Education, Labor, and Pensions Committee | Dec 12, 2017 |
CRS reports 2
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 2
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| IF11075 | FDA and Drug Prices: Facilitating Access to Generic Drugs | Resource | Jan 17, 2019 |
| R44810 | FDA Risk Evaluation and Mitigation Strategies (REMS): Description and Effect on Generic Drug Development | Report | Mar 16, 2018 |
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 974 | CREATES Act of 2018 | Identical bill | Jun 21, 2018 |
Titles 3
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
- Short Titles as Introduced
- CREATES Act of 2017
- Creating and Restoring Equal Access To Equivalent Samples Act of 2017
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Apr 27, 2017Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.